- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
回复 disan 的帖子
RNAi is used to target foreign genes. FDA is cautious because RNAi may accidentally silence a human gene, that is one of the reasons why FDA wants to proceed slowly.
The warning against REP9AC is equally valid( potentially causing intracellular build-up and ER stress).
For both ARC520 and REP9AC, we can only take their words that their treatments are "safe and well tolerated".
If you read the ARC520 presentation carefully(slide 34), hbvdna intergration does not mean the integration of complete cccDNA into the human genome, only fragments of the cccDNA are intergrated, for example, part or whole of S genes, X gene, and C gene. So, intergrated hbvdna cannot be used as a template to replicate a new HBV virion.
" Granted it was an extremely viremic chimp and one of the RNAi triggers was a mismatch, but still." - This means one of the RNAi triggers was a mismatch against HBV cccDNA, in chimp or human! As I say before, RNAi triggers should be designed against viral antigens' genes only! ARC520 presentation also gives you their reason(Slide 37, Loss of ARC-520 target sites explains lower KD of HBsAg in HBeAg neg chimps) why ARC520 does not work if part of cccDNA is lost during integration - nothing to do with the chimp's DNA.
RNA干扰是用于靶向并外国[/ B]的基因。 FDA是谨慎,因为RNA干扰可能会意外地沉默人类基因,这就是为什么FDA希望继续缓慢的原因之一。
针对REP9AC警告是同样有效(潜在造成的细胞内积聚和ER应激)。
对于这两种ARC520和REP9AC,我们只能把他们的话,他们的治疗是“安全且耐受性良好”。
如果你仔细阅读ARC520演示(幻灯片34),HBVDNA一体化并不意味着完全的cccDNA融入人类基因组中,cccDNA的只有片段综合型,例如,部分或全部小号的基因,X基因和C基因。所以,综合型HBVDNA不能用作模板复制一个新的HBV病毒粒子。
“当然这是一个非常病毒血症黑猩猩和RNAi的触发器之一是不匹配的,但还是。” - 这意味着所述RNAi触发器之一是抗HBV的cccDNA,一个错配中黑猩猩或人!正如我之前说的RNAi触发器的设计应针对病毒抗原“只有基因! ARC520表现也给你自己的原因(幻灯片37中,ARC-520的目标网站损失解释乙肝表面抗原HBeAg的NEG黑猩猩更低KD)为什么ARC520如果[B] cccDNA的流失部分不起作用[/ B]集成过程中 - 没有什么做与黑猩猩的DNA。
|
|